| | Study ID (name, year) | Intervention | Duration/follow-up | Adverse events | Outcome measures | | Trial group | Control group (essential treatment) |
| | Li, 2012 [20] | KFX, 10 mL, TID + essential treatment | Esomeprazole, 40 mg, QD, Po | 4 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Xiang, 2013 [21] | KFX, 10 mL, TID + essential treatment | Esomeprazole, 40 mg, QD, Po | 4 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Zhang, 2009 [22] | KFX, 10 mL, TID + essential treatment | Esomeprazole, 40 mg, QD, Po | 4 weeks/NR | T: 2 cases nausea, 1 case diarrhea; C: 2 cases nausea | Total efficacy rate, efficacy rate of gastroscopy | | Zhang, 2013 [23] | KFX, 10 mL, TID + essential treatment | Esomeprazole, 20 mg, QD, Po | 4 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Huang, 2014 [24] | KFX, 10 mL, TID + essential treatment | Omeprazole, 20 mg, BID, Po | 4 weeks/1 year | NR | Total efficacy rate, efficacy rate of gastroscopy, recurrence rate | | Huang, 2016 [25] | KFX, 10 mL, TID + omeprazole, 20 mg, QD, Po | Omeprazole, 20 mg, BID, Po | T: 28 days/NR C: 14 days/NR | NR | Total efficacy rate, clearance rate of HP | | McGrady, 2016 [26] | KFX, 10 mL, TID + essential treatment | Omeprazole, 20 mg, BID, Po | 4 weeks/NR | T: 1 case headache, 1 case nausea; C: 3 cases headache, 2 cases nausea, 2 cases constipation | Total efficacy rate | | Xuan, 2008 [27] | KFX, 10 mL, TID + omeprazole, 20 mg, QD, Po | Omeprazole, 20 mg, BID, Po | 4 weeks/NR | T: 1 case rash over axillae; C: 1 case insomnia | Total efficacy rate, efficacy rate of gastroscopy | | Zhu, 2016 [28] | KFX, 10 mL, TID + essential treatment | Lansoprazole, 30 mg, QD, Po | 2 weeks/NR | NO | Total efficacy rate, efficacy rate of gastroscopy | | Zhou, 2016 [29] | KFX, 10 mL, TID + essential treatment | Lansoprazole, 30 mg, QD, Po | 4 weeks/NR | T: 2 cases dizziness and diarrhea; C: 11 cases nausea and diarrhea | Total efficacy rate, efficacy rate of gastroscopy, inflammatory cytokines, T-lymphocyte subsets | | He, 2014 [30] | KFX, 10 mL, TID + essential treatment | Lansoprazole, 30 mg, QD, Po | 4 weeks/NR | NO | Total efficacy rate, efficacy rate of gastroscopy | | Chen, 2012 [31] | KFX, 10 mL, TID + essential treatment | Rabeprazole, 10 mg, QD, Po | 4 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Ou, 2014 [32] | KFX, 10 mL, TID + essential treatment | Rabeprazole, 10 mg, QD, Po | 5 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Yu, 2016 [33] | KFX, 10 mL, TID + essential treatment | Rabeprazole, 20 mg, QD, Po | 3 weeks/NR | NR | Total efficacy rate | | Chen, 2017 [15] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, BID, Po | 2 weeks/NR | T: 1 case rash; C: 2 cases nausea, 1 case rash | Total efficacy rate | | Fan, 2015 [34] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, QD, Po | 4 weeks/NR | T: NO; C: 5 cases diarrhea | Total efficacy rate, efficacy rate of gastroscopy, inflammatory cytokines, T-lymphocyte subsets, clearance rate of HP | | Liang, 2011 [35] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, BID, intravenous drip | 2 weeks/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Peng, 2010 [36] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, BID, Po | 10 days/NR | T: 1 case diarrhea; C: 2 cases diarrheoa, 1 case bellyache | Total efficacy rate | | Tian, 2015 [37] | KFX, 10 mL, QD + essential treatment | Pantoprazole, 40 mg, QD, Po | 1 month/NR | NR | Total efficacy rate, efficacy rate of gastroscopy | | Ye, 2007 [38] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, QD, Po | 4 weeks/NR | T: 4 cases digestive symptoms; C: 3 cases digestive symptoms | Total efficacy rate, efficacy rate of gastroscopy | | Zhang, 2015 [39] | KFX, 10 mL, TID + essential treatment | Pantoprazole, 40 mg, BID, intravenous drip | 1 week/half a year | T: 1 case diarrhea; C: 2 cases diarrhea, 1 case headache, 1 case rash | Total efficacy rate, recurrence rate | | Zhang, 2015 [40] | KFX, 10 mL, TID + omeprazole, 20 mg, QD, Po | Omeprazole, 20 mg, BID, Po | T: 4 weeks/NR C: 2 weeks/NR | T: 2 case diarrhea; C: NO | Total efficacy rate, clearance rate of HP |
|
|
